lame of the firm vith Complete				AJ.Mirza Pharma Karachi		
Manufacturer / mporter				Importer		
Iandatory lequirements.	YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:	YES/NO	In case of being Importers, the Firm should provi attested copies of the following documents also:		
ational Tax Number (NTN) of e Firm for Income Tax, and	YES	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA	Valid Drugs Sales License for the importer; and	YES	

Valid Product Registration

by the Firm for this bidding

Valid DRAP Approved Price

List of the quoted item/s.

competition.

3

NA

NA

Certificate issued by the DRAP for the item/s quoted

Valid Product Registration Certificate

competition; and

2

3

5

6

issued by the DRAP for the imported item/s quoted by the Firm for this bidding

Valid Agency Agreement with the Foreign

Principal Manufacturer entity/ies; and

Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the

quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm.

imported good/s. Non provision of this document shall lead to disqualification of

Valid DRAP approved Price List of the

the firm; and

quoted items.

Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted

Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ YES

Yes

Last year Income Tax Return of the Firm; and

Sale Tax Registration Certificate

Certificate of Professional Tax of

of the Firm; and

the Firm.

YES

YES

YES

2

3

		Raw material and its source gr	radation	Bio-Equivalence (BE	) / Bio- Similar (BS) or Bio-wa	iver (BW)	Clinical Trial/ C	Clinical studies assessing the safety and ef	ficacy of the	Cold Chain Facility		Product Sample for Physical	1)Substantial quantity of
		•active and •mactive		Study/Certificate	lab of SRA countries (Stringe		quoted drug. I	n case if the quoted item is Generic the st the Generic and not on the originator. (N	udies must be			Evaluation.	Supplies of anti-cancer medicines made to private
		(For API or finished product). I / multi-national manufacturer, Analytical/Quality Assurance/ manufacturing or marketing of of the following categories of t the Country of Origin to achiev grades.  Certificate of Analysis/ / Appre / Quality Assurance Certificate of the company shall be submi as a mandatory requirement. Importers must submit agency original manufacturer duly att company.	Approval Certificates for the feach quoted product from any the Drug Regulatory Authority of ve the corresponding evaluation oval eduly verified/attested by official littled along with the Technical Bid y agreement/ approval with the ested/verified by official of the material from the claimed source of purchase e.g. invoice etc.)	Authorities). (Attach BE/BS Certificate with evid countries. Bio-Equivalence (BE against the originate equivalence certifica branded generics re Certificate, duly atte to be submitted alor	lence as to its authenticity) i ) of the quoted product to or. Original innovator produc ate and shall get 10 marks au	rom Category A  be conducted ts do not require bio- tomatically. All other	performed on research artick		tust be an origina			Samples will be examined per following parameters as mentioned in Annex-I: a.Labeling and Packing Rules 1986 b.Outer packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	sector Teaching Hospitals
	Tabala Fashadia Passada												Performance (Last two years).
	Technical Evaluation Parameters		Category B – Approved By:  • Agência Nacional De Vigilância	Study/certificate accepted/certified by	BE/BS/BW certificate obtained for a quoted productfrom	No BE/BS/BW Certificate.	In case the study is	In case the study is published in Category "X" journal listed in HEC Journal Recognition	Studies/original article published	i) Certificate of compliance to cold	ii) Non- Compliance to	Satisfactory nsatisfacto	Good Performance Certificates     f these institutions must be
		Administration (US-FDA)	Sanitária (ANVIS), Brazil	a Category A Country	Category B Country (as		published in	System (HJRS) Database, 2 marks per original research article shall be awarded	in category "Y"	chain standards issued	international		produced in order to be eligible for
				Regulatory Authority. BE testing must be	mentioned at S No. 1 above).		journal listed in	maximum up to 6 marks).	journal of the HJRS shall not be	by an authorized third party e.g. DRAP,	reference standards or		1 mark per institution upto a maximum of 5 marks. Only supply
		•Medicines&BealthcareBrodu		done using at least 12			HEC Journal Recognition		awarded marks.	PSQCA, PCSIR.	absence of Cold		orders will not get any marks.
			Pakistan  •NationalPharmaceuticalControl	subjects. Bio-waiver is acceptable only to			System (HJRS)			The procuring entity	Chain requirements		3)The bidders have to undertake that they have never been
		• Therapeutic 6 oods Administr	Bureau (NPCB), Malaysia	injectable forms if			Database, 3 marks per			reserves the right to	mentioned in		blacklisted or debarred.
			•Bood & Drug Administration, South Korea	issued by Category A Country.			original			visit any cold chain facility for	Annex-I shall lead to disqualification		Maximum marks for this criterion
			•Ministry of Health, Egypt	Country.			research article			physical inspection /	of the relevant		are 5.
			•Ministry of Health, Turkey				shall be awarded			verification	product that		
			●@hina Food & Drug Administration				maximum up to				requires cold chain.		(iv) Those firms who have not been
		Japan	•Any other source not mentioned				9 marks).						regular in supplies for the Project
		•Swiss Agency For therapeutic drugs (Swiss-	in Category-A								In case if No cold chain facility for		"Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO
		medic), Switzerland									products		marks shall be deducted for poor
		•Bealth Canada									requiring		past performance irrespective of
		<ul> <li>■Bealth Sciences Authority (HAS), Singapore</li> </ul>									cold chain maintenance is		substantial supplies or Performance at any other institute.
		■National Administration of									present the firm ,	1 1	enormance at any other institute.
		Drugs, Food & Medical									product shall be		
		technology (ANMAT), Argentina									disqualified.		
											The procuring		
											entity reserves the right to visit		
1 1											any cold chain		

S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0 5	70
29	Capecitabine Tab 500mg		Capegard	40	0	0	0	0	0	0	0	5	0	1	0 4	50
71	Fulvestrant 250mg Inj.		Fulvest	0	30	10	0	0	0	0	0	5	0	1	0 4	50
83	Imatinib 100mg Cap		Imatib	40	0	10	0	0	3	2	0	5	0	1	0 4	65
85	Imatinib 400mg Cap		Imatib	40	0	10	0	0	3	2	0	5	0	Sample not provided	0 4	64
100	Letrozole 2.5mg Tab		Letara	40	0	10	0	0	0	0	0	5	0	1	0 4	60
138	Oxaliplatin 100mg Inj.		Oxaliplatin	0	30	10	0	0	6	2	0	5	0	1	0 4	58
140	Oxaliplatin 50mg Inj.		Oxaliplatin	0	30	10	0	0	6	2	0	5	0	1	0 4	58
155	Pemetrexed 100mg Inj		Pemsoh	0	30	10	0	0	3	0	0	5	0	1	0 4	53
156	Pemetrexed 500mg Inj.		Pemsoh	0	30	10	0	0	3	0	0	5	0	1	0 4	53
3	Abiraterone 250 mg Tab		Abirone	0	30	10	0	0	0	2	0	5	0	Sample not provided	0 4	51
20	Bortezomib 3.5mg Inj.		Bortesoh	0	30	10	0	0	0	0	0	5	0	1	0 4	50
76	Granisterone 3mg Inj.		Granicip	40	0	0	0	0	0	0	0	5	0	1	0 4	50
96	Lenalidomide 10mg Cap.		lenmid	40	0	0	0	0	0	0	0	5	0	Sample not provided	0 4	49
97	Lenalidomide 25mg Cap.		lenmid	40	0	0	0	0	0	0	0	5	0	Sample not provided	0 4	49
177	Sorafenib 200mg Tab.		Soranib	0	30	0	0	0	0	0	0	5	0	Sample not provided	0 4	39

	TECHNICAL EVALUATION PR	ROFORMA, FOR PROCUREMEN	IT OF MEDICINE FOR PROJECT TITLED " TREATME	ENT OF POOR CANCER PATIENTS"									
Name of the firm with Complete Address	ΛΛ ΟΠΛΟΜΛ ΚΛΟΛΟΠΙ												
Manufacturer / Importer			Importer										
	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		In case of being Importers, the Firm should provide attested copies of the following documents also:										

	Mandatory Requirements.	YES / NO	provide attested copies	ufacturer, the Firm should of the following documents also:	YES/NO
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA
2	Last year Income Tax Return of the Firm; and	YES	2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	NA
3	Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	NA
4	Certificate of Professional Tax of the Firm.	YES			

	being Importers, the Firm should provide I copies of the following documents also:	YES/NO	
1	Valid Drugs Sales License for the importer; and	YES	
2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES	
3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) / Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good's, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES	
5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	YES	
6	Valid DRAP approved Price List of the quoted items.	YES	

	Raw material and its source gradation	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW)	Clinical Trial/ Clinical studies assessing the safety and efficacy of the	Cold Chain Facility	Product Sample for Physical Evaluation.	Past Performance (Last two years).	
	•active and		quoted drug. In case if the quoted item is Generic the studies must be	·	, , , , , , , , , , , , , , , , , , , ,		
	•Ehactive	From an accredited lab of SRA countries (Stringent Regulatory	performed on the Generic and not on the originator. (Must be an		Samples will be examined per following	1) Good Performance Certificates of these	
			original research article)		parameters as mentioned in Annex-I:	institutions must be produced in order to be	
	(For API or finished product). i) The bidder (local manufacturer /	,			a.Labeling and Packing Rules 1986	eligible for 1 mark per institution upto a	
	multi-national manufacturer / importer)shall provide				b.Outer packing	maximum of 5 marks. Only supply orders will not	
	Analytical/Quality Assurance/ Approval Certificates for the				c.Inner packing	get any marks.	
	manufacturing or marketing of each quoted product from any of						
	the following categories of the Drug Regulatory Authority of the	(Attach BE/BS			d.Physical appearance.	3)The bidders have to undertake that they have	
	Country of Origin to achieve the corresponding evaluation grades	Certificate with evidence as to its authenticity) from Category A				never been blacklisted or debarred.	
		countries.			Product which		
	Certificate of Analysis/ / Approval				has unsatisfactory	Maximum marks for this criterion are 5.	
	/ Quality Assurance Certificate duly verified/attested by official or	f Bio-Equivalence (BE) of the quoted product to be conducted			packing/labeling		
	the company shall be submitted along with the Technical Bid as a	against the originator. Original innovator products do not require			will be technically		
	mandatory requirement.	bio- equivalence certificate and shall get 10 marks automatically.			Disqualified.	(iv) Those firms who have not been regular in	Total Techn
	Importers must submit agency agreement/ approval with the	All other branded generics require BE					Score
	original manufacturer duly attested/verified by official of the	All other branaca generies require be			Maximum marks for this criterion are 1.	Cancer Patients" at HMC. Peshawar. TWO marks	
	company.	Certificate, duly attested by an official of the company in			Waximum marks for this criterion are 1.	shall be deducted for poor past performance	
	Detailed purchase trail of raw material from the claimed source						
	shall be submitted (any proof of purchase e.g invoice etc.)	Pakistan is to be submitted along with the Technical Bid.				irrespective of substantial supplies or	
	Maximum marks for this criterion are 40.					Performance at any other institute.	
		Maximum marks for this criterion are 10.					
Technical Evaluation Parameters							1

	Technical Evalua	TUUI 1 dI dIIETET 3		Administration (US-FDA)  •European Medicines Agency (EMA)  •Medicines & Bealthcare Broduc ts Regulatory Agency (MHRA), UK	Organization (CDSCO), India **Drug Regulatory Authority, Pakistan **Bational@harmaceutical@ontrol Bureau (NPCB), Malaysia **Bood & Drug Administration, South Korea **Binistry of Health, Egypt **Binistry of Health, Turkey **Binistry of Bo. Drug	e accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 24 subjects. Bio-waiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).		In case the study is published in Category "W" journal listed in Category the HEC Journal Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	article published in	to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-! Shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
74	Gemcitabine	Inj. 200mg	Zefei	0	30	10	0	0	3	4	0	5	0	1	0	4	57
75	Gemcitabine	lnj. 1gm	Zefei	0	30	10	0	0	3	4	0	5	0	1	0	4	57

			TECHN	ICAL EVALUATION	I PROFOR	MA, FOR PROCUREMENT O	F MEDI	CINE FOR PROJECT TITLE	O " TREA	REATMENT OF POOR CANCER PATIENTS"
	Name of the firm with Complete Address						CUNI	NINGHAM PHARMA LA	HORE	E
	Manufacturer / Importer							MANUFACTURER		
	Mandatory Requirements.	YES / NO	rovide attested copies o	ufacturer, the Firm should of the following documents lso:	YES/NO		In case of attested	being Importers, the Firm should provide I copies of the following documents also:	YES/NO	NO
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES		Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NO		1	Valid Drugs Sales License for the importer; and	NA	
2	Last year Income Tax Return of the Firm; and	NO		Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	YES		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	NA	
3	Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	NO		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	NA	
4	Certificate of Professional Tax of the Firm.	YES		Valid cGMP certificate issued by DRAP or cGMP inspection report by the DRAP	NO	Expired	4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	NA	

NA

Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm;

Valid DRAP approved Price List of the quoted items.

Raw material and its source gradation	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW)	Clinical Trial/ Clinical studies assessing the safety and efficacy of the	Cold Chain Facility	Product Sample for Physical Evaluation.	Past Performance (Last two years).	
• active and	Study/Certificate	quoted drug. In case if the quoted item is Generic the studies must be	·			
•Bhactive	From an accredited lab of SRA countries (Stringent Regulatory	performed on the Generic and not on the originator. (Must be an		Samples will be examined per following	1) Good Performance Certificates of these	
(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer)shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marked of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis / Approval  / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement.  Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed source shall be submitted (any proof of purchase e.g invoice etc.)  Maximum marks for this criterion are 40.	From an accredited lab of SRA countries (Stringent Regulatory Authorities).  (Attach BE/BS  Certificate with evidence as to its authenticity) from Category A countries.  Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically. All other branded generics require BE  Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.  Maximum marks for this criterion are 10.	performed on the Generic and not on the originator. (Must be an original research article)		parameters as mentioned in Annex-I: a.Labeling and Packing Rules 1986 b.Outer packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing / labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3)The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in	Fotal Score

	TCHIICAI EVAIUA	RUVII 1 dI AHEUCI S		Category A – Approval By:  *Binited States Food & Drug Administration (US-FDA)  *Buropean Medicines Agency (EMA)  UK  *BinerapeuticBoods#dministration (TGA), Australia  - Windcinies Agency (MHRA), UK  *Bharmaceutical Medical Agency (PHARMAC), New Zealand  #Bharmaceutical & Medical Devices Agency (PMDA), Japan  *Swiss Agency (PF Therapeutic drugs (Swiss-medic),  Swiss Agency for therapeutic drugs (Swiss-medic),  Swiss Agency for therapeutic drugs (Swiss-medic),  *Weiterland  *Beath Sciences Authority (HAS), Singapore  *Bational Administration of Drugs, Food & Medical technology (AMMAT),  Argentina	Pakistan  *NationalPharmaceutical@ontrol t Bureau (NPCB), Malaysia  *Eood & Drug Administration, South Korea  *Ministry of Health, Egypt  *Ministry of Health, Turkey  *Ehina Food & Drug  Administration	e accepted/certifi ed by a Category A Country Regulatory Authority. BE testing must be done using at least 24 subjects. Bio-waiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).		In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/origina article published in category 'T'' journal of the HJRS shall not be awarded marks.	to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahorof Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
57	Eltrombopag	Tab. 25mg	Pagotras	0	30	0	0	0	0	0	0	0	0	0	0	0	30
58	Eltrombopag	Tab. 50mg	Pagotras	0	30	0	0	0	0	0	0	0	0	0	0	0	30

		TECH	INICAL EVALUATION PR	OFORMA	, FOR PROCUREMENT OF MEI	DICINE I	FOR PROJECT TITLED " T	REATME	NT OF POOR CAI	ICER PATIENTS"		
Name of the firm with Complete						AMGC	OMED, Islamabad					
Manufacturer / Importer							Importer					
Mandatory Requirements.	YES / NO		ing a Manufacturer, the Firm should ted copies of the following documents also:				eing Importers, the Firm should provide copies of the following documents also:	YES/NO				
National Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	N/A		1	Valid Drugs Sales License for the importer and	YES				
Last year Income Tax Return of the Firm; and		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding			2	Valid Product Registration Certificate issued by the DRAP for the imported item's quoted by the Firm for this bidding competition; and	YES				
Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	N/A		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES				
Certificate of Professional Tax of the Firm.	YES					4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) / Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES				
			·			5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and					
						6	Valid DRAP approved Price List of the quoted items.	YES				

	Technical Evaluation Parameters	Raw material and its source gradation **Bractive and **Bractive (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer)shall provide Analytical/Quality Assurance, Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis/ / Approval / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed source shall be submitted [any proof of purchase e.g invoice etc.)  Maximum marks for this criterion are 40.	Study/Certificate From an accredited lab of SRA countries (Stringent Regulatory Authorities).  (Attach BE/BS Certificate with evidence as to its authenticity) from Category A countries.  Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio-equivalence certificate and shall get 10 marks automatically. All other branded generics require BE Certificate, duly attested by an official of the company in	Clinical Trial/ Clinical Studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)		Samples will be examined per following parameters as mentioned in Annex-I: a.Labeling and Packing Rules 1986 b.Outer packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	Past Performance (Last two years).  1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3) The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
--	---------------------------------	---	--	---	--	---	--	-----------------------------

				Category A – Approval By:  -Binted States Food & Drug Administration (US-FDA) -Buropean Medicines Agency (EMA) -Medicines&BealthcareBrodu sts Regulatory Agency (MHRA), UK -MherapeuticBoodsMdministration (TGA), Australia -Pibarmaceutical Medical Agency (PHARMAC), New Zealand -Bharmaceutical Medical Devices Agency (PMDA), Japan -Bwiss Agency For therapeutic drugs (Swiss-medic), Switzerland -Bealth Canada -Beath Sciences Authority (HAS), Singapore -National Administration of Drugs, Food & Medical technology (ANMAT), Argentina	Organization (CDSCO), India  *Drug Regulatory Authority, Pakistan  *Bati ona!Bharmaceutica!Bontrol Bureau (NPCB), Malaysia  *Eood & Drug Administration, South Korea  *Ministry of Health, Egypt  *Binistry of Health, Turkey  *China Food & Drug  Administration  *Amy other source not mentioned  *Any other source not mentioned	e accepted/certifi ed by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	article published in category "Y" journal of the HJRS shall not be awarded marks.	cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that requires cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
	3 Aberaterone	250mg tab	Abyga	0	30	0	5	0	0	0	0	5	0	1	0	1	42
8	9 Irinotecan	100mg inj	Irinotecan Medac	40	0	0	0	0	0	0	0	5	0	1	0	1	47
10	3 Leuprolide acetate	11.25mg inj	Lorelin Depot	0	30	0	0	0	0	0	0	5	0	1	0	1	37
10	4 Leuprolide acetate	3.75mg inj	Lorelin Depot	0	30	0	0	0	0	0	0	5	0	1	0	1	37
13	8 Oxaliplatin	100mg inj	Oxaliplatin Medac	40	0	0	0	0	3	0	0	5	0	1	0	1	50
13	9 Oxaliplatin	150mg inj	Oxaliplatin Medac	40	0	0	0	0	3	0	0	5	0	1	0	1	50
14	0 Oxaliplatin	50mg inj	Oxaliplatin Medac	40	0	0	0	0	3	0	0	5	0	1	0	1	50
15	3 Filgrastim	300mcg Inj	Amgofil	0	30	0	0	0	0	0	0	5	0	1	0	1	37
18	1 Temozolomide	100mg Cap	Temomedac	40	0	0	0	0	0	0	0	5	0	1	0	1	47
18	2 Temozolomide	20mg Cap	Temomedac	40	0	0	0	0	0	0	0	5	0	1	0	1	47

		TECHNICAL EVALUATION PROF	ORMA, FOR PROCUREMENT OF ME	DICINE FOR PROJECT TITLED " TR	EATMEN	T OF POOR CAI	NCER PATIENTS"
Name of the firm with Complete Address				AGP LIMITED, KARACHI			
Manufacturer / Importer			II	MPORTER/MANUFACTURER			
Mandatory Requirements.	YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:	YES/NO	In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO		
National Tax Number (NTN) of the		Valid Drugs Manufacturing		Valid Drugs Sales License for the			

	Mandatory Requirements.	YES / NO	provide attested copies	afacturer, the Firm should of the following documents iso:	YES/NO
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	YES
2	Last year Income Tax Return of the Firm; and	YES		Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	YES
3	Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	NA
4	Certificate of Professional Tax of the Firm.	YES	4	Valid cGMP certificate issued by DRAP or cGMP inspection report by the DRAP	N/A

	being Importers, the Firm should provide copies of the following documents also:	YES/NO	
1	Valid Drugs Sales License for the importer; and	YES	
2	Valid Product Registration Certificate issued by the DRAP for the imported item's quoted by the Firm for this bidding competition; and	YES	
3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item's as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company sown letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES	
5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	Yes	
6	Valid DRAP approved Price List of the quoted items.	Yes	

Raw material and its source gradation  *Ritte wand  *Bractive  (For API or finished product). I) The bidder (local manufacturer / multi-national manufacture	A countries (Stringent Regulatory  Bamples will be examined per following parameters as mentioned in Annex-1:  a.Labeling and Packing Rules 1986  b. Outer packing  c.Inner packing  d.Physical appearance.  3)The bidders have to undertake that they have never been blacklisted or debarred.  Product which  has unsatisfactory  packing/labeling  will be technically  Disqualified.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Total Technicals Score  Cancer Patients' at HMC, Peshawar, TWO marks  Cancer Patients' at HMC, Peshawar, TWO marks
--	--

	ECCHINCAL EVALUATIVE E ALA	шккіз	Category A - Approval By:  - Britied States Food & Drug Administration (US-PDA) - Buropean Medicines Agency (EMA) - Bledicines Bleathtra reBroduct - Regulatory Agency (WHRA), UK - Brera peuti GBoodsildministrati on (TGA), Australia Bharmaceutical Medical Agency (PHAMA)C, New Zealand - Bharmaceutical & Medical Devices Agency (PMDA), Japan - Swiss Agency (PAMDA), Japan - Swiss Agency for therapeutic drugs (Swiss-medic), Switzerfand - Bealth Canada - Bealth	Pakistan ##Bitional#harmaceuticalEontrol Bureau (NPCB), Malaysia #Bood & Dung Administration, South Korea ##Ministry of Health, Egypt ##Ministry of Health, Turkey ##Dinar Tood & Drug Administration ##Any other source not mentioned in Category-A	e accepted/certifi ed by a Category A Country Regulatory Authority. BE testing must be done using at least 24 subjects. Bio- waiver is acceptable only	BE/BS/BW certificate obtained for a guoted productfrom Category 8 Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study, is published in Cutagory—Wr. journal listed in HEC Journal Recognition System (HRSE), Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	research article shall be awarded maximum up to 6 marks).	article publishe in category "Y	t	international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hoopitals namely: The Aga Khan University Hoopital, Karachi, Shaukat Khanum Hospital, Lahoref Peshawar and CMH, Rawalgand or to Hayatabat Medical Complex, Peshawar, Shifa Internitional hospital Islambad, with Good/Satisfactory Performance Certificates from these institutions (mandatory), Marks shall only be provided to those who provide good performance worthfacte issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks		
S.No Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70	
135 Ondansetrone	8mg Inj	Zofran	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	1	36	To be excluded
136 Ondansetrone	8mg Tab	Zofran	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	1	36	To be excluded
138 Oxaliplatin	100mg inj	Oxaliplatin Ebewe	0	30	0	5	0	3	0	0	5	0	1	0	1	45	
139 Oxaliplatin	150mg inj	Oxaliplatin Ebewe	0	30	0	5	0	3	0	0	5	0	1	0	1	45	
141 Paclitaxel	150mg inj	Paclitaxel Ebewe	40	0	0	0	0	6	0	0	5	0	1	0	1	53	
142 Paclitaxel	300mg Inj	Paclitaxel Ebewe	40	0	0	0	0	6	0	0	5	0	1	0	1	53	

e excluded due to contract manufacturing

excluded due to contract manufacturing.

	TECHNICAL EVALUATION P	ROFORMA, FOR PROCU	REMENT OF MEDICINE FOR PROJECT TITLED	TREATMENT OF POOR CANCER PAT	IENTS"
Name of the firm with Complete Address			Martin Dow Specialties, Kara	chi	
Manufacturer / Importer			Importer		
	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		In case of being Importers, the Firm should provide attested copies of the following documents also:		
Mandatory Requirements. YES / NO		YES/NO		YES/NO	
National Tax Number (NTN) of the Firm for Income Tax, and	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	N/A	Valid Drugs Sales License for the importer; and	YES	
Last year Income Tax Return of the Firm; and	Valid Product Registration Certificate issued by the DRAP for the item's quoted by the Firm for this bidding competition.	N/A	Valid Product Registration Certificate issued by the DRAP for the imported item's quoted by the Firm for this bidding competition; and	YES	
Sale Tax Registration Certificate of the Firm; and	Valid DRAP Approved Price List of the quoted item/s.	N/A	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	Yes	
Certificate of Professional Tax of the Firm.			Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	Yes	
			Valid Free Sale Certificate for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good's. Non provision of this document shall lead to disqualification of the firm; and	Yes	
			Valid DRAP approved Price List of the quoted items.	Yes	

Technical Evaluation Parameters
---------------------------------

				Category A – Approval By:  Binited States Food & Drug Administration (US-FDA)  Buropean Medicines Agency (EMA)  Burdpean Medicines Agency (EMA)  Medicines BleathcareBrod.  cts Regulatory Agency (MHRA), UK  BherapeuticSoodsBdministration (TGA), Australia.  Bharmaceutical Medical Agency (PHABMAC), New Zealand  Bharmaceutical & Medical Devices Agency (PMDA), Japan  -Swiss Agency For therapeutic drugs (Swiss- medic), Switzerland  -Bleath Sciences Authority (HAS), Singapore  -Batonal Administration of Drugs, Food & Medical technology (ANMAT), Argentina	- Ragin-call actional de Wilgillania Sanitária (ANVIS), Brazil Gentral Brugstandar d'Eontrol Organization (CDSCO), India - Brugs Regulatory Authority, Pakistan - National Bharmaceutical Eontrol Bureau (NPCB), Malaysia - Bood & Drug Administration, South Korea - Wilnistry of Health, Egypt - Wilnistry of Health, Turkey - Ehina Food & Drug Administration - Administration - Amy other source not mentioned	e accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 24 subjects. Biowaiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom 1 Category B Country (as mentioned at 5 No. 1 above).	I No BE/BS/BW Certificate.	In case the study is published in Category-Wr journal listed in HEC Journal Recognition System (HRSS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal Isted in HEC Journal Recognition System (HJRS) Database, 2 marks per originar research article shall be awarded maximum up to 6 marks).	article l published in	compliance to colc chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. The procuring entity reserves the right to visit any cold chain facility for	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-1 shall lead to disqualification of the relevant product that requires cold chain. In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified. The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals annely: The Age Xhan Unhersity Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shila Intentional hospital islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Maris shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
75	Granisetron	3mg/3ml Inj	Kytril	40	0	10	0	0	3	2	0	5	0	1	0	0	61
76	Granisetron	1mg Tab	Kytril	40	0	10	0	0	3	2	0	5	0	1	0	0	61

			TECHNICAL I	EVALUATION PRO	FORMA, I	FOR PROCUREMENT OF MED	DICINE F	OR PROJECT TITLED " TR	EATMEN	IT OF POOR	CANCER PATIENTS"
	Name of the firm with Complete Address					M	acter Ir	ternational, Karachi			
	Manufacturer / Importer						N	lanufacturer			
	Mandatory Requirements.	YES / NO	provide attested copies	nufacturer, the Firm should s of the following documents also:	YES/NO			eing Importers, the Firm should provide copies of the following documents also:	YES/NO		
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	YES		1	Valid Drugs Sales License for the importer, and	NA		
2	Last year Income Tax Return of the Firm; and	YES	2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	YES		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	NA		
3	Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	NO		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	NA		
4	Certificate of Professional Tax of the Firm.	YES	4	Valid cGMP certificate issued by DRAP or cGMP inspection report by the DRAP	YES		4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head	NA		

## Macter International, Karachi

## Manufacturer

	being Importers, the Firm should provide copies of the following documents also:		
		YES/NO	
1	Valid Drugs Sales License for the importer; and	NA	
2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	NA	
3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	NA	
4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on companys own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	NA	
5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	NA	
6	Valid DRAP approved Price List of the quoted items.	NA	

	Technical Evaluation Parameters			i) The bidder (local manufacturer / / importer) shall provide / Approval Certificates for the of each quoted product from any of e brug Regulatory Authority of the corresponding evaluation roval in the corresponding evaluation with the tested/verified by official of the variety of the corresponding evaluation of the co	Study/Certifica From an accree Authorities).  (Attach BE/BS Certificate with countries.  Bio-Equivalent against the ori bio- equivalent All other brand Certificate, dul Pakistan is to b	dited lab of SRA countries (Stri	ingent Regulatory  ity) from Category A  to be conducted oducts do not require marks automatically.	quoted drug.	Clinical studies assessing the safety and eff in case if the quoted item is Generic the stu the Generic and not on the originator. (M rch article)	idies must be	Cold Chain Facili	ty	Product Sample for Phys Samples will be examine parameters as mentione a.labeling and Packing R b.Outer packing c.Inner packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this	ed per following d in Annex-1: ules 1986	Past Performance (Last two years).  1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3) The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
		rs .	Category A – Approval By:  *Binted States Food & Drug Administration (US-FDA)  *European Medicines Agency (EMA)  *Betropean Medicines Agency (EMA)  *Betropean Medicines Agency (MHRA), UK  *Therapeutic Boods@ministration (TGA), Australia.  *Bharmaceutical Medical Agency (PHARMAC), New Zealand  *Bharmaceutical & Medical Devices Agency (PMDA), Japan  *Swiss Agency For therapeutic drugs (Swiss- medic), Switzerland  *Bealth Canada  *Bealth Sciences Authority (HAS), Singapore  *National Administration of Drugs, Food & Medical technology (ANMAT), Argentina	Category B – Approved By: *AgénciaNacional@eligilância Sanitária (ANVIS), Brazil *EentralBrug\$tandardEontrol Organization (CDSCO), India *Drug Regulatory Authority, Pakistan *NationalBharmaceutical@ontrol Bureau (NPCB), Malaysia *Eood & Drug Administration, South Korea *Binistry of Health, Egypt *Winistry of Health, Turkey *Ehina Food & Drug Administration *Amy other source not mentioned in Category-A	Study/certificat e accepted/certificat ed by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-acceptable only to injectable forms if Issued by Category A Country.	BE/BS/BW certificate obtained for a quoted productfrom Category B country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is study is published in Category "W" journal listed in HEC Journal Recognition System (HIRSD) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/originiarticle published in category "Y" journal of the HIRS shall no be awarded marks.	i) Certificate of compliance to cold chain standards issued by an authorized third part veg. DRAP, PSQCA, PCSIR. The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex! shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
64 Erythropoeitin	2000 IU inj	MAC Epo	0	30	0	0	0	0	0	0	5	0	1	0	1	37
64 Erythropoeitin	10000 IU inj	MAC Epo	0	30	0	0	0	0	0	0	5	0	1	0	1	37
152 Pegfilgratim	6mg inj	Pegstim	40	0	0	5	0	0	0	0	5	0	1	0	1	52
195 Zoledronic Acid	4mg inj	Macdronic	0	30	0	0	0	0	0	0	5	0	1	0	1	37

Name of the firm with Complete Address	ח				Lab Diag	nostics, Rawalpindi		
Manufacturer / Importer						Importer		
Mandatory Requirements	YES / NO		fanufacturer, the Firm should ies of the following documents also:	YES/NO		being Importers, the Firm should provide copies of the following documents also:	YES/NO	
National Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA .	1	Valid Drugs Sales License for the importer; and	YES	
Last year Income Tax Return of th Firm; and	YES	2		NA	2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES	
Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	NA .	3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	

Product (COMP) of the Principal Manufacturer for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good's, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm, and

Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm;

Valid DRAP approved Price List of the

quoted items.

				Raw material and its source g	adation	Bio-Equivalence (BE) / Bio-Similar (BS) or Bio	o-waiver (BW)		Clinical studies assessing the safety and effi		Cold Chain Facili	ty	Product Sample for Phys	sical Evaluation.	Past Performance (Last two years).	
				multi-national manufacturer/ Analytical/Quality Assurance/ manufacturing or marketing o the following categories of the Country of Origin to achieve t grades.  Certificate of Analysis/ / Appr / Quality Assurance Certificat of the company shall be subm as a mandatory requirement. Importers must submit agency original manufacturer duly att company.	Approval Certificates for the f each quoted product from any of Drug Regulatory Authority of the ne corresponding evaluation oval duly verified/attested by official titted along with the Technical Bid agreement/ approval with the ested/verified by official of the material from the claimed source of purchase e.g. invoice etc.)	Study/Certificate From an accredited lab of SRA countries (Stri Authorities).  (Attach BE/BS Certificate with evidence as to its authentic countries.  Bio-Equivalence (BE) of the quoted product against the originator. Original innovator pro bio- equivalence certificate and shall get 10: All other branded generics require BE Certificate, duly attested by an official of th Pakistan is to be submitted along with the To Maximum marks for this criterion are 10.	to be conducted to be conducted oducts do not require marks automatically.	performed on original resear	n case if the quoted item is Generic the stu the Generic and not on the originator. (Mi th article)				Samples will be examine parameters as mentione a.Labeling and Packing fb. Outer packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this	ed in Annex-I: Tules 1986	1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3) The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
	Technical E	valuation Paran	neters	cts Regulatory Agency (MHRA), UK - ¶herapeutidGoodsAdministration (TGA), Australia. - Bharmaceutical Medical Agency (PHARMAC), New Zealand - Bharmaceutical & Medical Devices Agency (PMDA),	Category B – Approved By:  **RigéncialNacionalBe@igilância Sanitária (ANVIS), Brazil  **BentrailBrug®tandard@ontrol Organization (CDSCO), India  **Brug Regulatory Authority, Pakistan **BationalBharmaceutical@ontrol Bureau (NPCB), Malaysia  **Bood & Drug Administration, South Korea  **Blinistry of Health, Egypt  **Blinistry of Health, Turkey  **Blinistry of Health, Turke	Study/certificat e aucepted/certifi ed by a Category & Country (as mentioned at 5 No. 1 above).  Category A Authority, BE testing must be done using at least 24 subjects. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.	No BE/BS/BW Certificate.	In case the study is ubulished in Category "W" in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HRSD) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in category "Y" journal of the HJRS shall not be awarded marks.	i) Certificate of compliance to code chain standards issued by an authorized third party e.g. DRAP, PSCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospital's namely. The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahrore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medicial Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10 5	0	9	6	0	5	0	1	0	5	70
12	Bendamustine	100 mg Inj.	Bendamustine	0	0	0 0	0	0	0	0	5	0	1	0	2	8
19	Bortezomib	3.5mg inj.	Bortezomib	0	0	0 0	0	0	0	0	5	0	1	0	2	8
44	Dacarbazine	200mg inj.	Dacarbazine	0	0	0 0	0	0	0	0	5	0	1	0	2	8
95	Lenalidomide	10mg Cap	Lenalidomide	0	0	0 0	0	0	0	0	5	0	1	0	2	8
127	Nab Paclitaxel	100mg inj	Nab Paclid	0	0	0 0	0	0	0	0	5	0	1	0	2	8
149	Peg-asparginase	3750 IU	Pegasparginase	0	30	0 0	0	3	0	0	5	0	1	0	2	41

		TECHNIC	AL EVALUATION P	PROFORM	A, FOR PROCUREMENT OF MEDICIN	E FOR PROJECT TITLED	" TREATI	MENT OF
Name of the firm with Complete Address					Ge	etz pharma, Karachi		
Manufacturer / Importer						Importer		
Mandatory Requirements.	YES / NO	provide attested copies	ufacturer, the Firm should of the following documents also:	YES/NO		eing Importers, the Firm should provide opies of the following documents also:	YES/NO	
National Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP): and	NA	1	Valid Drugs Sales License for the importe and	YES	
Last year Income Tax Return of the Firm; and	YES			NA	2	Valid Product Registration Certificate issued by the DRAP for the imported item quoted by the Firm for this bidding competition; and	YES	
Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	NA	3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
Certificate of Professional Tax of the Firm.	Yes					Valid cGMP/ Certificate of Pharmaceutica Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal	1 YES	

Manufacturer for the quoted item/s as

Manulacturer for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good's, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm, and

Valid Free Sale Certificate for the quoted item's as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm;

Valid DRAP approved Price List of the quoted items.

E C C C C C C C C C C C C C C C C C C C	Will the and What are and will are and a will are and a way and a way and a way and a way	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate From an accredited lab of SRA countries (Stringent Regulatory Authorities).  (Attach BE/BS Certificate with evidence as to its authenticity) from Category A countries.  Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically. All other branded generics require BE Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.  Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)	Cold Chain Facility	Product Sample for Physical Evaluation.  Samples will be examined per following parameters as mentioned in Annex-I: a.Labeling and Packing Rules 1986 b. Outer packing d. Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	Past Performance (Last two years).  1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks.  3)The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.
Technical Evaluation Parameters						

					Administration (US-FDA)	Sanitária (ANVIS), Brazil  -BentralBrugBlandeOntrol Organization (CDSCO), India  -Brug Regulatory Authority, Pakistan  -BationalBharmaceuticalBontrol Bureau (NPCB), Malaysia  -Bood & Drug Administration, South Korea  -Bilinistry of Health, Egypt  -Bilinistry of Health, Turkey  -Bilinistry of Acministration	е	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).		Studies/original article published in category "Y" journal of the HJRS shall not be awarded marks.	standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1]Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Intentional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.	No	litem Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
	185	Truastuzumab	440mg IV	Trastuget	40	0	0	5	0	6	0	0	5	0	1	0	0	57

			TECHNICAL EVALUATION PRO	ORMA, FOR I	PROCUREMENT OF MEDICINE	FOR P	PROJECT TITLED " TREATI	MENT OF I	POOR CANCER PATIENTS"
	Name of the firm with Complete Address				н	IMME	EL, LAHORE		
	Manufacturer / Importer					IMP	PORTER		
	Mandatory Requirements.	YES / NO	In case of being a Manufacturer, the Firm sh provide attested copies of the following docum also:		In	n case of be attested co	eing Importers, the Firm should provide opies of the following documents also:	YES/NO	
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES	Valid Drugs Manufactt License issued by the E Regulatory Authority o Pakistan (DRAP); and	ugs		1	Valid Drugs Sales License for the importer; and	/ES	
2	Last year Income Tax Return of the Firm; and	YES	Valid Product Registra Certificate issued by th  2 DRAP for the item/s qt by the Firm for this bid competition.	oted		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	/ES	
3	Sale Tax Registration Certificate of the Firm; and	YES	Valid DRAP Approved F  3 List of the quoted item/s.	ce			Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	/ES	
4	Certificate of Professional Tax of the Firm.	YES				4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	/ES	

	**Bictive and **Binative (For API or finished product). i) The bidder (local manufacturer / minorter) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis/ / Approval / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed source shall be submitted (any proof of purchase e.g. invoice etc.)	[Attach BE/BS Certificate with evidence as to its authenticity) from Category A countries.  Bio-Equivalence (BE) of the quoted product to be conducted	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)	Cold Chain Facility	Product Sample for Physical Evaluation.  Samples will be examined per following parameters as mentioned in Annex-I: a.labeling and Packing Rules 1986 b. Outer packing c.lnner packing d. Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	Past Performance (Last two years).  1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3) The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
Technical Evaluation Parameters							

Valid Free Sale Certificate for the quoted item's as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm;

Valid DRAP approved Price List of the quoted items.

				Category A – Approval By:  *Bnited States Food & Drug Administration (US-FDA)  *European Medicines Agency (EMA)  *Beropean Medicines Agency (EMA)  *Begulatory Agency (MHRA), UK  *Therapeuti cBoods#dministration (TGA), Australia.  *Pharmaceutical Medical Agency (PHARMAC), New Zealand  *Bharmaceutical & Medical Devices Agency (PMDA), Japan  *Swiss Agency For therapeutic drugs (Swiss- medic), Switzerland  *Beath Canada  *Beath Sciences Authority (HAS), Singapore  *Bational Administration of Drugs, Food & Medical technology (ANMAT), Argentina	Category B – Approved By:  **AgénciaNacional®e®igilância Sanităria (ANVIS), Brazil "BentralBrugaMandard@ontrol Organization (CDSCO), India **Brug Regulatory Authority, Pakistan **National®harmaceutical@ontrol Bureau (NPCB), Malaysia **Bood & Drug Administration, South Korea **Winistry of Health, Egypt **Winistry of Health, Turkey **Ehina Food & Drug Administration **Any other source not mentioned in Category-A	e	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	study is published in Category "W"		article published in category "Y" journal of the	I) Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that requires cold chain. In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified. The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khamum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islambad, with Good/Satisfactory Performance Certificates from these institutions (mandatony). Marks shall only be provided to those who provide good performance certificate Issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
19	Bortezomib	3.5mg inj	Bortezomib Pharmidea	0	30	0	0	0	0	0	0	5	0	1	0	3	39
16	Bicalutamide	50mg tab	Casomid	0	30	0	0	0	0	0	0	5	0	1	0	3	39
29	Carboplatin	150mg inj	Carplatu	0	30	0	0	0	0	0	0	5	0	1	0	3	39
30	Carboplatin	450mg inj	Carplatu	0	30	0	0	0	0	0	0	5	0	1	0	3	39
194	Zoledronic Acid	4mg inj	Zolonko	0	30	0	0	0	0	0	0	5	0	1	0	3	39
34	Cisplatin	50mg inj	Cipintu	0	30	0	0	0	0	0	0	5	0	1	0	3	39
54	Doxorubicin	50mg inj	Doxo Onko	0	30	0	0	0	0	0	0	5	0	1	0	3	39
21	Cabazitaxel	60mg inj	Cabazitaxel Ever	0	30	0	0	0	0	0	0	5	0	1	0	3	39
70	Fulvestrant	250mg inj	Fulvestrant Ever	0	30	0	0	0	0	0	0	5	0	1	0	3	39
77	Ibrutinib	140mg cap	Ibrutix	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	3	38
57	Eltrombopag	50mg tab	Elbonix	0	30	0	5	0	0	0	0	5	0	1	0	3	44
37	Crizotinib	250mg cap	Crizonix	0	30	0	5	0	0	0	0	5	0	Sample not provided	0	3	43
3	Abiraterone Acetate	250mg tab	Abiteron	0	30	0	0	0	0	0	0	5	0	1	0	3	39
95	Linalidomide	10mg tab	Linamide	0	30	0	5	0	0	0	0	5	0	1	0	3	44
96	Linalidomide	25mg tab	Linamide	0	30	0	5	0	0	0	0	5	0	1	0	3	44
97	Lenvatinib	10mg tab	Lenvanix	0	30	0	5	0	0	0	0	5	0	1	0	3	44
98	Lenvatinib	4mg tab	Lenvanix	0	30	0	5	0	0	0	0	5	0	1	0	3	44

	1			, ,													
127	Nab-Paclitaxel	100mg inj	Nab-Xelpac	0	30	0	0	0	0	0	0	5	0	1	0	3	39
128	Niltotinib	200mg cap	Nilonix	0	30	0	5	0	0	0	0	5	0	1	0	3	44
136	Osimertinib	80mg tab	Tegrix	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	3	38
142	Palonosetrone	0.25mg inj	Paloxi	0	30	0	0	0	0	0	0	5	0	1	0	3	39
144	Palbociclib	125mg tab	Palbonix	0	30	0	0	0	0	0	0	5	0	1	0	3	39
167	Regorafenib	40mg tab	Regonix	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	3	38
176	Sorafenib	200mg tab	Soranix	0	30	0	5	0	0	0	0	5	0	1	0	3	44
88	Irinotecan	100mg inj	Irinotecan Aqvida	40	0	0	0	0	0	0	0	5	0	Sample not provided	0	3	48
139	Oxaliplatin	50mg inj	Oxaliplatin Aqvida	40	0	0	0	0	0	0	0	5	0	1	0	3	49
137	Oxaliplatin	100mg inj	Oxaliplatin Aqvida	40	0	0	0	0	0	0	0	5	0	1	0	3	49
140	Paclitaxel	150mg inj	Paclitaxel Aqvida	40	0	0	0	0	0	0	0	5	0	1	0	3	49
141	Paclitaxel	300mg inj	Paclitaxel Aqvida	40	0	0	0	0	0	0	0	5	0	1	0	3	49
52	Docetaxel	20mg inj	Docetaxel Aqvida	40	0	0	0	0	0	0	0	5	0	1	0	3	49
53	Docetaxel	80mg inj	Docetaxel Aqvida	40	0	0	0	0	0	0	0	5	0	Sample not provided	0	3	48

Name of the firm with Complete Address					Merixil Pharma	Islamabad			
Manufacturer /									
mporter					Import	er			
Mandatory Requirements.	YES / NO	In case of being a Manufactt attested copies of the fo	rer, the Firm should provide llowing documents also:	YES/NO	should pro	eing Importers, the Firm vide attested copies of the ing documents also:	YES/NO		
sational Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA	1	Valid Drugs Sales License for the importer; and	YES		
ast year Income Tax Return of the irm; and	YES	2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding	NA	2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for	YES		
ale Tax Registration Certificate of the Firm; and	YES	3	competition.  Valid DRAP Approved Price List of the quoted item/s.	NA	3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies;	YES		
Certificate of Professional Tax of the Trm.	YES				4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item's as issued by relevant authority of drejs in of the country of origin of the quoted imported good's, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm, and		Valid CGMP/COPP of Bendamustine, Zoledronic Acid, Pacifitasel, Lutrate, Filgrastim, Temozolamide are not present in the original bid. Not fulfilling the mandatory criterion.	
					5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s.	NO	Valid free sale/\COPPs not poresent for some items	
					6	Valid DRAP approved Price List of the quoted	No		

Raw material and its source gradation	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW)	Clinical Trial/ Clinical studies assessing the safety and	Cold Chain Facility Produ	uct Sample for Physical	Past Performance (Last two years).	
	Study/Certificate	efficacy of the quoted drug. In case if the quoted item is	Evalu	uation.		
• inactive		Generic the studies must be performed on the Generic			1) Good Performance Certificates of	
**Ihactive  (For API or finished product). i) The bidder (local manufacturer / multinational manufacturer / importer)shall provide Analytical/Quality Assurance/Approval Certifice for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis/ / Approval  / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of purchase rule in Chiefical for the company. Detailed purchase trail or barretial from the claimed source shall be submitted (any proof of purchase e.g invoice etc.) Maximum marks for this criterion are 40.	From an accredited lab of SRA countries (Stringent Regulatory Authorities).	Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)	Samp follov ment a.l.ab 1986 b.Dut c.Innn d.Phy Produ has u packit will b Disqu	ples will be examined per wing parameters as tioned in Annex-1: beleling and Packing Rules it repacking ger packing sysical appearance. Suct which unsatisfactory ing/labeling be technically ualified.	1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3)The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or	:
Technical Evaluation Parameters						

				Category A – Approval By:  *Brited States Food & Drug  Administration (US-FDA)  *European Medicines Agency (EMA)  *Medicines_Bitealthcare@roducts  Regulatory Agency (MHRA), UK  *TherapeuticGoodsadministration  (TGA), Australia  *Pharmaceutical Medical Agency  (PHARMAC), New Zealand  *Pharmaceutical & Medical Devices  Agency (PMAD), Japan  *Wiss Agency For therapeutic drugs  (Swiss-medic), Switzerland  *Bealth Canada  *Bealth C	Category B – Approved By:  **RefenciaBacional#e#igilancia Sanifaria (ANN), Brazil  **GentralBrugBlandardEontrol Organization (CDSCO), India **Brug Regulatory Authority, Palistran **Battonal#harmaceutical#ontrol Bureau (RNCB), Malaysia **Send Surg Administration, South Korea **Hinistry of Health, Egypt **Ministry of Health, Turkey **Ehina Food & Destination of Sendination **Arry other source not mentioned in Category-A	accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 24 subjects. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.		No BE/BS/BW Certificate.	In case the study is used to the study is uphalshed in Category "W" in pural listed in HEC Journal journal listed in HEC Journal System (HRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	journal listed in HEC Journal Recognition System	article published in category "Y" journal of the HJRS shall not	i) Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to vist any cold chain facility for physical inspection / verification	international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of	Satisfactory Unsatisfactory	1]Substantial quantity of Supplies of anti- cancer medicines made to private sector Teaching Hospitals namely. The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provide to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only. I mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1 0	5	70
13	Bendamustine	100mg Inj	Seacross	40	0	0	0	0	0	0	0	0	0	1 0	0	41
29	Capecitabine	500mg tab	Capecitabine Normon	40	0	10	0	0	0	0	0	5	0	1 0	3	59
53	Docetaxel	20mg inj	Biodoce	40	0	0	0	0	0	0	0	5	0	1 0	3	49
54	Docetaxel	80mg inj	Biodoce	40	0	0	0	0	0	0	0	5	0	1 0	3	49
68	Exemestane	25mg tab	Normon	40	0	10	0	0	0	0	0	5	0	1 0	3	59
84	Imatnib	100mg tab	Imatinib Normon	40	0	10	0	0	0	0	0	5	0	1 0	3	59
106	Leuproline	22.5mg Inj	Lutrate	Not fulfilling the mandatory criteria of valid CGMP and COPP from the country of origin	0	Bioeq study of Lipotec is provided while the quoted brand is Lutrate	0	0	0	0	0	5	0	1 0	3	9
135	Ondansetron	8mg Inj	Ondansetron Norm	a 40	0	0	0	0	0	0	0	5	0	1 0	3	49
142	Paclitaxel	300mg Inj	Biopac	Not fulfilling the mandatory criteria of valid CGMP and COPP from the country of origin. COPP expired	0	0	0	0	0	0	0	5	0	1 0	3	9
153	Filgrastim	300mcg Inj	Topneuter	Not fulfilling the mandatory criteria of valid CGMP and COPP from the country of origin. COPP expired	0	0	0	0	0	0	0	5	0	1 0	3	9
181	Temozolomide	100mg Cap	Temoergin	0	30	10	0	0	0	0	0	5	0	1 0	3	49
182	Temozolomide	20mg Cap	Temoergin	0	30	10	0	0	0	0	0	5	0	1 0	3	49
195	Zoledronic acid	4mg Inj	Zoledronic acid normon	40	0	0	0	0	0	0	0	5	0	1 0	3	49

				•			OR PROJECT TITLED " TF			
Name of the firm with Complete Address							PharmaSol			
Manufacturer / Importer						M	lanufacturer			
			facturer, the Firm should provide ne following documents also:		In	case of be	ing Importers, the Firm should provide opies of the following documents also:			
Mandatory Requirements.	YES / NO			YES/NO				YES/NO		
National Tax Number (NTN) of the Firm for Income Tax, and	YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	YES		1	Valid Drugs Sales License for the importer; and	N/A		
Last year Income Tax Return of the Firm; and	YES	2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.			_	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	N/A		
Sale Tax Registration Certificate of the Firm; and	YES	3	Valid DRAP Approved Price List of the quoted item/s.	YES		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	N/A		
Certificate of Professional Tax of the Firm.	YES	4	Valid cGMP certificate issued by DRAP or cGMP inspection report by the DRAP	YES		4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) Certificate of Medicinal Product (COPP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted inported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	N/A		
						5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	N/A		
						6	Valid DRAP approved Price List of the quoted items.	N/A		

			Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW)	Clinical Trial/ Clinical studies assessing the safety and efficacy of the	Cold Chain Facility	Product Sample for Physical Evaluation.	Past Performance (Last two years).	
		• active and	Study/Certificate	quoted drug. In case if the quoted item is Generic the studies must be				
		•Bhactive	From an accredited lab of SRA countries (Stringent Regulatory	performed on the Generic and not on the originator. (Must be an		Samples will be examined per following	1) Good Performance Certificates of these	
			Authorities).	original research article)		parameters as mentioned in Annex-I:	institutions must be produced in order to be	
		(For API or finished product). i) The bidder (local manufacturer / multi-	,			a.Labeling and Packing Rules 1986	eligible for 1 mark per institution upto a	
		national manufacturer / importer)shall provide Analytical/Quality				b.Outer packing	maximum of 5 marks. Only supply orders will not	
		Assurance/ Approval Certificates for the manufacturing or marketing of					get any marks.	
		each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the	(Attach BE/BS				3)The bidders have to undertake that they have	
		corresponding evaluation grades.	Certificate with evidence as to its authenticity) from Category A				never been blacklisted or debarred.	
			countries.			Product which		
		Certificate of Analysis / / Approval					Maximum marks for this criterion are 5.	
		/ Quality Assurance Certificate duly verified/attested by official of the	Bio-Equivalence (BE) of the quoted product to be conducted			packing/labeling	The Annual Control of the Control of	
			against the originator. Original innovator products do not require			will be technically		Total
		mandatory requirement.	bio- equivalence certificate and shall get 10 marks automatically.				(iv) Those firms who have not been regular in	Technical
		Importers must submit agency agreement/ approval with the original	All other branded generics require BE				supplies for the Project "Treatment of Poor	Score
		manufacturer duly attested/verified by official of the company.					Cancer Patients" at HMC, Peshawar, TWO marks	Score
		Detailed purchase trail of raw material from the claimed source shall be	Certificate, duly attested by an official of the company in				shall be deducted for poor past performance	
		submitted (any proof of purchase e.g invoice etc.)	Pakistan is to be submitted along with the Technical Bid.				irrespective of substantial supplies or	
		Maximum marks for this criterion are 40.	and the second and th				Performance at any other institute.	
			Maximum marks for this criterion are 10.				renormance at any other institute.	
			Maximum marks for this criterion are 10.					
	Technical Evaluation Parameters							

				Category A – Approval By:  *Bnited States Food & Drug Administration (US-FDA)  *Buropean Medicines Agency (EMA)  *Buropean Medicines Agency (EMA)  *Wedicines&Bealthcare@roduc  ts Regulatory Agency (MHRA), UK  *BherapeuticBoods&dministrat ion T(TaA), Australia.  *Bharmaceutical Medical Agency (PHARMAC), New Zealand  *Bharmaceutical Medical  *Bharmaceutical & Medical  *Bharmaceutical Medical  *B	Korea  Ministry of Health, Egypt  Ministry of Health, Turkey  China Food & Drug Administration  Any other source not mentioned in	ed by a Category A Country	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	article published in category "Y" journal of the	i) Certificate of compliance to cold chain standards issued by an authorized third part ye. g. DRAP, PSQCA, PCSIR. The procuring entity reserves the right to vist any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-i shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional Hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
2	5 flurouracil	500mg/10ml inj	Flurosol	0	30	0	0	0	0	0	0	5	0	1	0	2	38
17	Bicalutamide	50mg tab	Bitamid	40	0	0	0	0	0	0	0	5	0	Sample not provided	0	2	47 37
29	Capcitabine	500mg tab	Capcita	0	30	0	0	0	0	0	0	5	0	Sample not provided Sample not provided	0	2	37
31	Carboplatin	450 mg/45ml Inj.	Carbosol	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
35	Cisplatin	50mg/50ml inj	Cispatin	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
44	Cytarabine	500mg Inj	Cytorox	0	30	0	0	0	0	0	0	5	0	1	0	2	48
53	Docetaxel trihydrate	20mg/5ml inj	Dotaxol	40	0	0	0	0	0	0	0	5	0	1	0	2	48
54	Docetaxel trihydrate	80mg/5ml	Dotaxol	40	0	0	0	0	0	0	0	5	0	1	0	2	38
57	Eltrombopag	25mg tab	Eltrom	0	30	0	0	0	0	0	0	5	0	1	0	2	38
58	Eltrombopag	50mg tab	Eltrom	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
	Epirubicin Hcl	10mg/5ml inj	Rubisol	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
	Epirubicin Hcl	50mg/25ml inj	Rubisol	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
	Erlotinib	150mg tab	Erlonib	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
83	Exemestane Imatinib	25mg tab 100mg Cap	Xemest Glynib	0	30	0	5	0	0	0	0	5	0	1	0	2	43
	Imatinib	400mg Cap	Glynib	0	30	0	5	0	0	0	0	5	0	1	0	2	43
89	Irinotecan	100mg inj	Irinosol	40	0	0	0	0	0	0	0	5	0	Sample not provided	0	2	47
94	Lapatinib	250mg tab	Lepta	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
116	Methotrexate	1g/40ml inj	Trexate	40	0	0	0	0	0	0	0	5	0	Sample not provided	0	2	47

115	Methotrexate	10mg tab	Trexate	40	0	0	0	0	0	0	0	5	0	Sample not provided	0	2	47
117	Methotrexate	50mg/2ml	Trexate	40	0	0	0	0	0	0	0	5	0	1	0	2	48
129	Nilotinib	200mg cap	Nitonib	0	30	0	0	0	0	0	0	5	0	1	0	2	38
138	Oxaliplatin	100mg inj	Oxalisol	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
140	Oxaliplatin	50mg inj	Oxalisol	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
141	Paclitaxel	150mg/25ml inj	Petaxel	40	0	0	0	0	0	0	0	5	0	1	0	2	48
142	Paclitaxel	300mg/50ml inj	Petaxel	40	0	0	0	0	0	0	0	5	0	1	0	2	48
177	Sorefinib tosylate	200mg tab	Sonib	0	30	0	5	0	0	0	0	5	0	1	0	2	43
178	Sunitinib maleate	50mg cap	Sunetic	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
181	Temozolamide	100mg Cap	Zolomid	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
183	Thalidomide	100mg cap	Thalimid	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	2	37
192	Vinblastine Sulphate	10mg/10ml inj	Blasvin	40	0	0	0	0	0	0	0	5	0	1	0	2	48
193	Vincristine	1mg/1ml inj	Crisvin	40	0	0	0	0	0	0	0	5	0	1	0	2	48
194	Vincristine	2mg/2ml inj	Crisvin	40	0	0	0	0	0	0	0	5	0	1	0	2	48

			TECHNICAL EVALUATION PROF	DRMA, FO	R PROCUREMENT OF MEDICINE	FOR	PROJECT TITLED " TREAT	MENT (	OF POOR CAN	NCER PATIENTS"						
	Name of the firm with Complete Address				Pfizer Pa	akista	nn Limited, karachi									
	Manufacturer / Importer		Importer  In case of being a Manufacturer, the Firm should													
	Mandatory Requirements.	YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:				ing Importers, the Firm should provide pies of the following documents also:	YES/NO								
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA		1	Valid Drugs Sales License for the importer; and	YES								
2	Last year Income Tax Return of the Firm; and	YES	Valid Product Registration Certificate issued by the DRAP for the item's quoted by the Firm for this bidding competition.	NA		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES								
3	Sale Tax Registration Certificate of the Firm; and	YES	Valid DRAP Approved Price List of the quoted item/s.	NA			Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES								

Certificate of Professional Tax of the YES

		YES/NO	
1	Valid Drugs Sales License for the importer; and	YES	
2	Valid Product Registration Certificate issued by the DRAP for the imported item's quoted by the Firm for this bidding competition; and	YES	
3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES	
5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	YES	
6	Valid DRAP approved Price List of the quoted items.	YES	

		**Ective and **Ihactive    (For API or finished product). I) The bidder (local manufacturer / multi-national manufacturer / importer)shall provide    Analytical/Quality Assurance / Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis / / Approval / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed source shall be submitted (any proof of purchase e.g. invoice etc.)	[Attach BE/BS Certificate with evidence as to its authenticity] from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)	·	Product Sample for Physical Evaluation.  Samples will be examined per following parameters as mentioned in Annex-I: a.Labeling and Packing Rules 1986 b.Outer packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	Past Performance (Last two years).  1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3) The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
--	--	--	--	---	---	--	--	-----------------------------

					Administration (US-FDA)	Category B – Approved By:  *RgenciaNacionalideMigilancia Sanitária (ANVIS), Brazil GentralDrugisMandardiontrol Organization (CDSCO), India Þrug Regulatory Authority, Pakistan *National@harmaceutical@ontrol Bureau (NPCB), Malaysia *Bood & Drug Administration, South Korea *Winistry of Health, Eypt *Winistry of Health, Turkey *Ehina Food & Drug Administration *Almy other source not mentioned in Category-A	e	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	article published in category "Y"		ii) Non-Compilance to international reference standards or absence of Cold Chain requirements mentioned in Annex-1 shall lead to disqualification of the relevant product that requires cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely. The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamada, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item	n Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
2	20 Bort	tezomib	3.5mg inj	Pfizer Bortezomib	40	0	0	0	0	0	0	0	5	0	1	0	2	48
14	11 Pacl	litaxel	150mg Inj	Anzatext	40	0	0	0	0	6	0	0	5	0	sample not provided	0	2	53
1	39 Irino	otecan	Inj. 100mg	Campto	40	0	10	0	0	9	0	0	5	0	1	0	2	67
	90 Irino	otecan	Inj, 40mg	Campto	40	0	10	0	0	9	0	0	5	0	1	0	2	67
	58 Exer	mestane	25mg tab	Aromasin	0	30	10	0	0	6	0	0	5	0	1	0	2	54
14	14 Palb	oociclib	100mg cap	Ibrance	40	0	10	0	0	9	0	0	5	0	1	0	2	67
14	15 Palb	oociclib	125mg cap	Ibrance	40	0	10	0	0	9	0	0	5	0	1	0	2	67
17	78 Suni	itinib	50mg cap	Sutent	40	0	10	0	0	6	0	0	5	0	1	0	2	64
18	35 Tras	stuzumab	440mg inj	Trazimera	40	0	10	0	0	9	0	0	5	0	1	0	2	67

	TECHNICAL EVALUATION PROFORMA, FO	R PROCUREMENT OF MEDICINE FOR PROJECT TITLED " 1	REATMENT OF POOR CANCER PATIENTS"
Name of the firm with Complete Address		Novartis, Karachi	
Manufacturer / Importer		Importer	
Mandatory Requirements. YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:  YES/NO	In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO
National Tax Number (NTN) of the Firm for Income Tax, and	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	Valid Drugs Sales License for the importer; and	YES
Last year Income Tax Return of the Firm; and	Valid Product Registration NA Certificate issued by the	Valid Product Registration Certificate issued by the DRAP for the imported item/s	YYES

DRAP for the item/s quoted

by the Firm for this bidding

List of the quoted item/s.

Valid DRAP Approved Price NA

competition.

2

3

2

4

the Firm; and

Sale Tax Registration Certificate of YES

Certificate of Professional Tax of the YES

quoted by the Firm for this bidding

Principal Manufacturer entity/ies; and

the certificate shall lead to disqualification

Valid Free Sale Certificate for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and Valid DRAP approved Price List of the

Valid Agency Agreement with the Foreign YES

Valid cGMP/ Certificate of Pharmaceutical Product (COPP) Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of

competition; and

of the firm. and

quoted items.

2

Technical Evaluation Parameters	Raw material and its source gradation *Bactive and *Bhactive  (For API or finished product). i) The bidder (local manufacturer multi-national manufacturer / importer)shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any the following categories of the Drug Regulatory Authority of th Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis/ / Approval / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bic as a mandatory requirement.  Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed sourc shall be submitted (any proof of purchase e.g. invoice etc.)  Maximum marks for this criterion are 40.	Study/Certifica From an accree Authorities).  of (Attach BE/BS Certificate with countries.  Bio-Equivalence against the origing bio-equivalence All other brance.  Certificate, dul Pakistan is to be	dited lab of SRA countries (Str	ingent Regulatory  ity) from Category A  to be conducted oducts do not require marks automatically.	quoted drug. I	Clinical studies assessing the safety and eff n case if the quoted item is Generic the stu the Generic and not on the originator. (M ch article)	udies must be	Cold Chain Facili		Product Sample for Physi Samples will be examine parameters as mentione a.Labeling and Packing Ri b.Outer packing d.Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified.	d per following d in Annex-I: ules 1986	Past Performance (Last two years).  1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3) The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
	Category A – Approval By:  Binited States Food & Drug Administration (US-POA)  European Medicines Agency (EMA)  Bedicines Bealthcare Brodu cts Regulatory Agency (MHRA), UK  Brerapeuti Goods Administration (TGA), Australia, albarmaceutical Medical Agency (PHARMAC), New Zealand  Bharmaceutical & Medical Devices Agency (PMDA), Japan  Buss Agency (PMDA), Japan  Bealth Sciences Authority (HAS), Singapore Bational Administration of Drugs, Food & Medical technology (ANMAT), Argentina	e accepted/certifi ed by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio- waiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at 5 No. 1 above).	Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HBS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	"Studies/original article published in category "Y" journal of the HJRS shall not be awarded marks.	i) Certificate of compliance to compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-1 shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain.  In case if No cold chain facility for products present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals amenly: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMMr, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No Item Generic Name Strength, Dosage form Brand Na	ne 40 30	10	5	0	9	6	0	5	0	1	0	5	70
66 Everolimus Smg tab Afinitor	40 0	10	0	0	6	0	0	5	0	1	0	4	66
67 Everolimus 10mg tab Afinitor	40 0	10	0	0	6	0	0	5	0	1	0	4	66
57 Eltrombopag 25mg tab Revolade	40 0	10	0	0	3	0	0	5	0	1	0	4	63
58 Eltrombopag 50mg tab Revolade	40 0	10	0	0	3	0	0	5	0	1	0	4	63
84 Imatinib 100mg tab Glivec	40 0	10	0	0	6	0	0	5	0	1	0	4	66
173 Ruxolitinib 5mg tab Jakavi	40 0	10	0	0	9	0	0	5	0	Sample not provided	0	4	68
174 Ruxolitinib 15mg tab Jakavi	40 0	10	0	0	9	0	0	5	0	1	0	4	69
169 Ribociclib 200mg tab Kisqali	40 0	10	0	0	6	0	0	5	0	1	0	4	66
94 Lapatinib 250mg tab Tykerb	40 0	10	0	0	0	0	0	5	0	1	0	4	60

100 Letrozole	2.5mg tab	Femara	40	0	10	0	0	0	0	0	5	0	Sample not provided	0	4	59
149 Pazopanib	400mg tab	Votrient	40	0	10	0	0	6	0	0	5	0	1	0	4	66
175 Ocreotide LAR	20mg inj	Sandostatin LAR	0	30	10	0	0	3	0	0	5	0	1	0	4	53
176 Ocreotide LAR	30mg inj	Sandostatin LAR	0	30	10	0	0	3	0	0	5	0	1	0	4	53
129 Nilotinib	200mg cap	Tasigna	40	0	10	0	0	3	0	0	5	0	1	0	4	63
195 Zoledronic Acid	4mg inj	Zometa	40	0	10	0	0	0	2	0	5	0	Sample not provided	0	4	61

		TECHNICAL EVALUATION	PROFORMA, FOR PRO	OCUREMENT OF MEDICINE FOR PROJECT TITL	ED " TREATMENT OF POC	DR CANCER PATIENTS"
Name of the firm with Complete Address				ONCOGENE PHARMA KARA	СНІ	
Manufacturer / Importer				MANUFACTURER		
Mandatory Requirements.	YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:	YES/NO	In case of being Importers, the Firm should provid attested copies of the following documents also:		
National Tax Number (NTN) of the Firm for Income Tax, and	YES	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	YES	Valid Drugs Sales License for the importer; and	NA	
Last year Income Tax Return of the Firm; and	YES	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding	YES	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this biddin competition; and	ig NA	

List of the quoted item/s.

YES

Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and

Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacture for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate

acceptable. Non provision of the certificate shall lead to disqualification of the firm.

Valid Free Sale Certificate for the quoted tiem/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of

Valid DRAP approved Price List of the quoted items.

the firm; and

NA

NA

Certificate of the Firm; and

Certificate of Professional Tax of the Firm.

YES

YES

Raw material and its source gradation *Bictive and *Bhactive  [For API or finished product]. i) The bidder (local manufacturer / multi-national manufacturer / importer)shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the crosponding evaluation grades.  Certificate of Analysis / Approval / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed source shall be submitted (any proof of purchase e.g. invoice etc.) Maximum marks for this criterion are 40.	Bio-Equivalence (BE) / Bio-Similar (BS) or Bio-waiver (BW) Study/Certificate From an accredited lab of SRA countries (Stringent Regulatory Authorities).  (Attach BE/BS Certificate with evidence as to its authenticity) from Category ountries.  Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio-equivalence certificate and shall get 10 marks automatically. All other branded generics require BE Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.  Maximum marks for this criterion are 10.		Cold Chain Facility	Product Sample for Physical Evaluation.  Samples will be examined per following parameters as mentioned in Annex-I: a.Labeling and Packing Rules 1986  b. Outer packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	(iv) Those firms who have not been regular in	Total Technical Score
--	--	--	---------------------	--	---	-----------------------------

	icinical	Lyawawu i ai	auruis	Category A – Approval By:  "Binited States Food & Drug Administration (US-FDA)  "Buropean Medicines Agency (EMA)  "Bitedicines Blealthcare Broduc ts Regulatory Agency (MHRA), UK  "BiterapeuticBoods Ministration (TGA), Australia.  "Biterapeutical Medical Agency (PHARMAC), New Zealand  "Bharmaceutical Medical Devices Agency (PMDA), Japan  "Biterapeutical Medical Devices Agency (PMDA), Japan  "Biterapeutical Medical Devices Agency (PMDA), Japan  "Biterapeutical Medical Beath Sciences Authority (HAS), Singapore  "Bational Administration of Drugs, Food & Medical technology (ANMAT), Argentina	Bood & Drug Administration,     South Korea     Ministry of Health, Egypt     Ministry of Health, Turkey     China Food & Drug     Administration	e accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio- waiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at 5 No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal Isted in HEC Journal Recognition System (HRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	article published in	cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.	international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Internttional hospital Islamabad, with Good/Satsfactory Performance Certificates from these institutions (mandatory). Marks shall only be provide to those who provide good performance certificates issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
3	Abiraterone	250 mg Tab.	Abytiga	0	30	0	0	0	0	0	0	5	0	1	0	0	36
4	Abiraterone	500mg Tab.	Abytiga	0	30	0	0	0	0	0	0	5	0	Sample not provided	0	0	35
29	Capecitabine	500 mg Tab.	Pectibine	40	0	0	0	0	0	0	0	5	0	Sample not provided	0	0	45
84	Imatinib	100 mg Tab.	Imatigliv	40	0	0	0	0	0	0	0	5	0	1	0	0	46
129	Nilotinib	200 mg Cap.	Nilosigna	0	30	0	0	0	0	0	0	5	0	1	0	0	36
149	Pazopanib	400mg Tab.	Pazorene	40	0	0	0	0	0	0	0	5	0	1	0	0	46

	1							
			TECHNICAL EVALUATION PROP	ORMA, FOR PROCUREMENT OF N	MEDICINE FOR PROJECT TITLED " TREA	ATMENT OF POOR CANC	ER PATIENTS"	
	Name of the firm with Complete Address				Roche Pakistan Limitted			
	Manufacturer / Importer				Importer			
	Mandatory Requirements.	YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO		
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		Valid Drugs Sales License for the importer; and	YES		
2	Last year Income Tax Return of the Firm; and	/ES	Valid Product Registration Certificate issued by the DRAP for the item/s quoted		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES		

by the Firm for this bidding competition.

Valid DRAP Approved Price
List of the quoted item/s.

3

Sale Tax Registration Certificate of the Firm; and

Firm.

4

Certificate of Professional Tax of the YES

competition; and

Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and

Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal

Manufacturer for the quoted item/s as

Manulacturer for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good's, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm, and

Valid Free Sale Certificate for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm;

Valid DRAP approved Price List of the quoted items.

Raw material and its source gradation  *Rictive and  *Bactive  (For API or finished product). I) The bidder (local manufacturer multi-national manufacturer / importer)shall provide  Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis // Approval / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement.  Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed source shall be submitted along with the Technical Shall bushieted (any proof of purchase e.g. invoke etc.)  Maximum marks for this criterion are 40.  Technical Evaluation Parameters	Regulatory Performed on the Generic and not on the originator. (Must be an original research article)  Samples will be examined per following parameters as mentioned in Annex-1: a.Labeling and Packing Rules 1986 b. Outer packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Samples will be examined per following parameters as mentioned in Annex-1: a.Labeling and Packing Rules 1986 b. Outer packing c.Inner packing d.Physical appearance.  3) The bidders have to undertake that they have never been blacklisted or debarred.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  (iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor soat performance  Total Technicore Score
--	--

				Category A – Approval By:  -Binited States Food & Drug Administration (US-FDA) -Buropean Medicines Agency (EMA) -Bredicines BleathcareBrodu tis Regulatory Agency (MHRA), UK -Breapeut Geods administration (TGA), AustraliaBharmaceutical Medical Agency (PHARMAC), New Zealand -Bharmaceutical & Medical Devices Agency (PMDA), Japan -Bwiss Agency Fon -Bwis	Pakistan  *Bationalibarmaceutical@ontrol Bureau (NPCB), Malaysia  *Bood & Drug Administration, South Korea  *Ministry of Health, Egypt  *Ministry of Health, Turkey  *Ehina Food & Drug  Administration	e	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	In case the study is published in Category "W" journal listed ir HEC Journal Recognition System (HJRS). Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in category "Y" journal of the HJRS shall not be awarded marks.	i) Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahone/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islambada, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5 0	9	6	0	5	0	1	0	5	70
5	Adotrastuzumab	100mg inj	Kadcyla	40	0	10	0 0	0	0	0	5	0	1	0	4	60
5	Adotrastuzumab	160mg inj	Kadcyla	40	0	10	0 0	0	0	0	5	0	1	0	4	60
6	Alectinib	150mg cap	Alecensa	40	0	10	0 0	3	0	0	5	0	1	0	4	63
9	Atezolizumab	1200mg inj	Tecentriq	40	0	10	0 0	9	0	0	5	0	1	0	4	69
15	Bevacizumab	100mg/4ml inj	Avastin	40	0	10	0 0	9	0	0	5	0	1	0	4	69
16	Bevacizumab	400mg/16ml inj	Avastin	40	0	10	0 0	9	0	0	5	0	1	0	4	69
131	Obinutuzumab	1000mg inj	Gazyva	40	0	10	0 0	9	0	0	5	0	1	0	4	69
158	Pertuzumab	420mg inj	Perjeta	40	0	10	0 0	0	0	0	5	0	1	0	4	60
159	Pertuzumab/Trastuzumab	600/600mg inj	Phesgo	40	0	10	0 0	6	0	0	5	0	1	0	4	66
160	Pertuzumab/Trastuzumab	1200/600 mg inj	Phesgo	40	0	10	0 0	6	0	0	5	0	1	0	4	66
161	Polatuzumab	140mg inj	Polivy	40	0	10	0 0	6	0	0	5	0	1	0	4	66
172	Rituximab IV	100mg /10ml inj	Ristova	40	0	10	0 0	9	0	0	5	0	1	0	4	69
	Rituximab IV	500mg /10ml inj	Ristova	40	0	10	0 0	9	0	0	5	0	1	0	4	69
170	Rituximab SC	1400mg/11.7ml	Mabthera	40	0	10	0 0	9	0	0	5	0	1	0	4	69
185	Trastuzumab	440mg IV inj	Herceptin	40	0	10	0 0	9	0	0	5	0	1	0	4	69
186	Trastuzumab	600mg SC inj	Herceptin	40	0	10	0 0	9	0	0	5	0	1	0	4	69

			TECHNICAL EVALUATION	N PROFORMA, FOR PROCUREMEN	T OF MEDICINE FOR PROJECT TITLE	D " TREA	TMENT OF PO	OR CANCER PATIENTS"
	Name of the firm with Complete Address				PHARMEVO KARACHI			
	Manufacturer / Importer				IMPORTER			
	Mandatory Requirements.	YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:	YES/NO	In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO		
1	National Tax Number (NTN) of the Firm for Income Tax, and	NO	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP): and		Valid Drugs Sales License for the importer; and	NO		
2	Last year Income Tax Return of the Firm; and	NO	Valid Product Registration Certificate issued by the 2 DRAP for the item's quoted by the Firm for this bidding competition.		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	NO		
3	Sale Tax Registration Certificate of the Firm; and	NO	Valid DRAP Approved Price List of the quoted item/s.		Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	NO		

Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal

the certificate shall lead to disqualification of the firm. and

Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm;

Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Certificate on company's own letter head shall not be acceptable. Non provision of

Certificate of Professional Tax of the

NO

3

Raw material and its source gradation	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW)	Clinical Trial/ Clinical studies assessing the safety and efficacy of the	Cold Chain Facility	Product Sample for Physical Evaluation.	Past Performance (Last two years).	_
• active and	Study/Certificate	quoted drug. In case if the quoted item is Generic the studies must be	Cold Chain Facility	Froduct sample for Fifysical Evaluation.	rast renormance (Last two years).	
• Enactive	From an accredited lab of SRA countries (Stringent Regulatory	performed on the Generic and not on the originator. (Must be an		Samples will be examined per following	1) Good Performance Certificates of these	
	Authorities).	original research article)		parameters as mentioned in Annex-I:	institutions must be produced in order to be	
(For API or finished product). i) The bidder (local manufacturer /	Authorities).	original research article)		a.Labeling and Packing Rules 1986	eligible for 1 mark per institution upto a	
multi-national manufacturer / importer)shall provide				b.Outer packing	maximum of 5 marks. Only supply orders will not	<b>1</b>
Analytical/Quality Assurance/ Approval Certificates for the				c.Inner packing	get any marks.	`
manufacturing or marketing of each quoted product from any of	(Attach BE/BS			d.Physical appearance.	3)The bidders have to undertake that they have	
	Certificate with evidence as to its authenticity) from Category A			u.i nysicai appearance.	never been blacklisted or debarred.	
country or Origin to achieve the corresponding evaluation grades.	countries.			Product which	never been blacklisted of debarred.	
Certificate of Analysis/ / Approval	countries.			has unsatisfactory	Maximum marks for this criterion are 5.	
	Bio-Equivalence (BE) of the quoted product to be conducted			packing/labeling	Waximum marks for this criterion are 5.	
the company shall be submitted along with the Technical Bid as a	against the originator. Original innovator products do not require			will be technically		
mandatory requirement.	bio- equivalence certificate and shall get 10 marks automatically.			Disqualified.	(iv) Those firms who have not been regular in	т
Importers must submit agency agreement/ approval with the	All other branded generics require BE			Disquainieu.	supplies for the Project "Treatment of Poor	s
original manufacturer duly attested/verified by official of the	All other branded generics require be			Maximum marks for this criterion are 1.	Cancer Patients" at HMC, Peshawar, TWO marks	٠,
company.	Certificate, duly attested by an official of the company in			Maximum marks for this differion are 1	shall be deducted for poor past performance	1
Detailed purchase trail of raw material from the claimed source	Pakistan is to be submitted along with the Technical Bid.				irrespective of substantial supplies or	
shall be submitted (any proof of purchase e.g invoice etc.)  Maximum marks for this criterion are 40.	akistan is to be submitted along with the recinical blu.				Performance at any other institute.	
Maximum marks for this criterion are 40.	Maximum marks for this criterion are 10.				renormance at any other institute.	
	The state of the s					

	Technical Evalu	authi i ai ameters		UK  *IberapeuticBoodsAdministration (TGA), Australia.  *Bharmaceutical Medical Agency (PHARMAC), New Zealand  *Bharmaceutical & Medical Devices Agency (PMDA), Japan	Organization (CDSCO), India  *Drug Regulatory Authority, Pakistan  *NationalPharmaceuticalEontrol Bureau (NPCB), Malaysia  *Ecod & Drug Administration, South Korea  *Ministry of Health, Egypt  *Ministry of Health, Turkey  *Ehina Food & Drug  Administration	Study/certificat e accepted/certifi ed by a Category A Country Regulatory Authority, BE testing must be done using at least 24 subjects. Bio- waiver is acceptable only to injectable forms if issued by Category A Country.	ctfrom C	No BE/BS/BW Certificate.	In case the study is used to study is published in Category "W" journal listed in HEC Journal Recognition on System (HIRS) Database, 3 marks per original awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in category "Y" journal of the HJRS shall not be awarded marks.	i) Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / werification	Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that	Satisfactory	Unsatisfactory	1]Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpilodi or to Hayatabad Medical Complex, Peshawar , Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate Issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10 5		0	9	6	0	5	0	1	0	5	70
	Bevacizumab	100mg Inj	Bevec	0	0	0 0		0	0	0	0	0	0	sample not provided	0	0	0
	Bevacizumab	40mg Inj	Bevec	0	0	0 0		0	0	0	0	0	0	sample not provided	0	0	0
	Rituximab	100mg Inj.	Rituxim	0	0	0 0		0	0	0	0	0	0	sample not provided	0	0	0
	Rituximab	500mg Inj	Rituxim	0	0	0 0		0	0	0	0	0	0	sample not provided	0	0	0
	Trastuzumab	440mg Inj	Traszeptin	0	0	0 0		0	0	0	0	0	0	sample not provided	0	0	0

			TECHNICAL EV	/ALUATION PROF	ORMA, FO	T OF MEDICINE F	OR PROJECT TITLED " TRE	ATMEN	T OF POOR CA	CER PATIEN	NTS"		
	Name of the firm with Complete Address					CCL Phar	ma Limitted Lahore						
	Manufacturer / Importer						Importer						
	Mandatory Requirements.	YES / NO	provide attested copies	ufacturer, the Firm should of the following documents also:	YES/NO		f being Importers, the Firm should provide d copies of the following documents also:	YES/NO					
1	National Tax Number (NTN) of the Firm for Income Tax, and	res	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA	1	Valid Drugs Sales License for the importer; and	YES					
2	Last year Income Tax Return of the Firm; and	YES	2		NA	2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES					
3	Sale Tax Registration Certificate of the Firm; and	YES	3		NA	3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	NO					
4	Certificate of Professional Tax of the Firm.	NO				4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm, and	NO	COPP of both products expired				
			1		1	5	Valid Free Sale Certificate for the quoted item's as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	NO					
						6	Valid DRAP approved Price List of the quoted items.	NO					

	Raw material and its source gradation	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW)	Clinical Trial/ Clinical studies assessing the safety and efficacy of the	Cold Chain Facility	Product Sample for Physical Evaluation.	Past Performance (Last two years).	
		Study/Certificate	quoted drug. In case if the quoted item is Generic the studies must be				
	• Enactive	From an accredited lab of SRA countries (Stringent Regulatory	performed on the Generic and not on the originator. (Must be an		Samples will be examined per following	1) Good Performance Certificates of these	
	(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / limporter/shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.  Certificate of Analysis / / Approval / Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.  Detailed purchase trail of raw material from the claimed source shall be submitted (any proof of purchase e.g. invoice etc.)	Authorities).  (Attach BE/BS Certificate with evidence as to its authenticity) from Category A countries.  Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require	performed on the Generic and not on the originator. (Must be an original research article)		parameters as mentioned in Annex-I: a.Labeling and Packing Rules 1986 b.Outer packing c.Inner packing d.Physical appearance.  Product which has unsatisfactory packing/labeling will be technically Disqualified.  Maximum marks for this criterion are 1.	institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. Only supply orders will not get any marks.  3)The bidders have to undertake that they have never been blacklisted or debarred.  Maximum marks for this criterion are 5.  (iv) Those firms who have not been regular in	Total Technical Score
Technical Evaluation Parameters							

				(EMA)	Category B – Approved By:  *AgenciaNacional@digilancia Sanitaria (ANVIS), Brazil  *Bentral® vigatandard@ontrol Organization (CDSCO), India  *Bruga (Regulatory Authority, Pakistan  *BationalBharmaceuticalBontrol Bureau (NPCB), Malaysia  *Bod & Drug Administration, South Korea  *Binistry of Health, Egypt  *Ministry of Health, Turkey  *Ehina Food & Drug  Administration  *Amy other source not mentioned  c in Category-A	e accepted/certifi ed by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Biowaiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS). Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	article published in category "Y" journal of the HJRS shall not be awarded marks.	compliance to	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain adility for products requiring cold chain facility for product sequiring cold chain aniantenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
15	Bevacizumab	100mg/4ml inj	Stivant	0	0	0	0	0	3	0	0	0	0	Sample not provided	0	0	3
16	Bevacizumab	400mg/16ml inj	Stivant	0	0	0	0	0	3	0	0	0	0	Sample not provided	0	0	3
172	Rituximab IV	100mg /10ml inj	Zytux	0	0	0	0	0	0	0	0	0	0	Sample not provided	0	0	0
171	Rituximab IV	500mg /10ml inj	Zytux	0	0	0	0	0	0	0	0	0	0	Sample not provided	0	0	0

Name of the firm with	Umar Pharma, Peshawar Importer													
Manufacturer / Importer														
Mandatory Requirements.	YES / NO	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:	YES/NO	In case of l attested	oeing Importers, the Firm should provide copies of the following documents also:	YES/NO								
National Tax Number (NTN) of the Firm for Income Tax, and	YES	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and	YES								
Last year Income Tax Return of the Firm; and	YES	Valid Product Registration Certificate issued by the DRAP for the item's quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES								
Sale Tax Registration Certificate of the Firm;	YES	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES								
and Certificate of Professional Tax of the Firm.	YES			4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP) (Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES								
		1		5	Valid Free Sale Certificate for the quoted item's as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and Valid DRAP approved Price List of the	NA YES								

	Raw material and its source gradation	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW)	Clinical Trial/ Clinical studies assessing the safety and efficacy of the	Cold Chain Facility	Product Sample for Physical Evaluation.	Past Performance (Last two years).	
		Study/Certificate	quoted drug. In case if the quoted item is Generic the studies must be				
	•Bhactive	From an accredited lab of SRA countries (Stringent Regulatory	performed on the Generic and not on the originator. (Must be an		Samples will be examined per following	1) Good Performance Certificates of these	
	(For API or finished product). i) The bidder (local manufacturer /	Authorities).	original research article)		parameters as mentioned in Annex-I:	institutions must be produced in order to be	
	multi-national manufacturer / importer) shall provide	,	,			eligible for 1 mark per institution upto a	
	Analytical/Quality Assurance/ Approval Certificates for the					maximum of 5 marks. Only supply orders will not	
	manufacturing or marketing of each quoted product from any of					get any marks.	
	the following categories of the Drug Regulatory Authority of the	(Attach BE/BS				3)The bidders have to undertake that they have	
		Certificate with evidence as to its authenticity) from Category A			,	never been blacklisted or debarred.	
	g. ddc5i	,				never been blacklisted or debarred.	
	Certificate of Analysis/ / Approval / Quality Assurance Certificate duly verified/attested by official	countries.			Product which		
						Maximum marks for this criterion are 5.	
		Bio-Equivalence (BE) of the quoted product to be conducted			packing/labeling		
	Importors must submit agansu agreement / approval with the	against the originator. Original innovator products do not require			will be technically		Total Technical
	original manufacturer duly attested/verified by official of the	bio- equivalence certificate and shall get 10 marks automatically.				(iv) Those firms who have not been regular in	
	company	All other branded generics require BE				supplies for the Project "Treatment of Poor	Score
	Detailed purchase trail of raw material from the claimed source				Maximum marks for this criterion are 1.	Cancer Patients" at HMC, Peshawar, TWO marks	
	shall be submitted (any proof of purchase e.g invoice etc.)	Certificate, duly attested by an official of the company in				shall be deducted for poor past performance	
		Pakistan is to be submitted along with the Technical Bid.				irrespective of substantial supplies or	
		_				Performance at any other institute.	
		Maximum marks for this criterion are 10.				<u> </u>	
Technical Evaluation Parameters							
 			•				

---

					- #agénciaNacional®e®igiláncia Sanitária (ANVIS), Brazil GentrialBrug®tandard®ontrol Organization (CDSCO), India - #brug Regulatory Authority, Pakistan - #Bational®harmaceutical®ontrol Bureau (NPCB), Malaysia - #Bood & Drug Administration, South Korea - #Ministry of Health, Egypt - #Ministry of Health, Turkey - #Ministry of Health, Turkey - #Ministry of therauty	e accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 24 subjects. Biowaiver is acceptable only to injectable	BE/BS/BW certificate obtained for a quoted productfrom Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in HEC Journal al Recognition System (HJRS) Database, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in category "Y" journal of the HJRS shall not be awarded marks.	i) Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	ii) Non-Compliance to international reference standards or absence of Cold Chain requirements mentioned in Annex-I shall lead to disqualification of the relevant product that requires cold chain.  In case if No cold chain facility for products requiring cold chain maintenance is present the firm / product shall be disqualified.  The procuring entity reserves the right to visit any cold chain facility for physical inspection / verification	Satisfactory	Unsatisfactory	1)Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar and CMH, Rawalpindi or to Hayatabad Medical Complex, Peshawar, Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders only.  1 mark per agreement up to a maximum of 5 marks	
S.No	Item Generic Name	Strength, Dosage form	Brand Name	40	30	10	5	0	9	6	0	5	0	1	0	5	70
6	Ansatrozole	1mg tab	Geneplex	40	0	0	0	0	0	0	0	5	0	1	0	2	48
16	Bicalutamide	50mg tab	Bicamide	40	0	0	5	0	0	0	0	5	0	1	0	2	53
99	Letrozole	2.5mg tab	Femaplex	40	0	10	0	0	0	0	0	5	0	1	0	2	58
179	Tamoxifen	10mg tab	Zymoplex	0	30	0	0	0	0	0	0	5	0	1	0	2	38
180	Tamoxifen	20mg tab	Zymoplex	0	30	0	0	0	0	0	0	5	0	1	0	2	38